Deutsche Bank on Eli Lilly (LLY): 'CB-1 Appetite Suppression Looks Underwhelming'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Eli Lilly (LLY) call put ratio 2.1 calls to 1 put as share price up 1.9%
September 20, 2024 11:03 AM EDTEli Lilly & Co. (NYSE: LLY) 30-day option implied volatility is at 27; compared to its 52-week range of 22 to 56. Call put ratio 2.1 calls to 1 put with focus on September 950 calls.
... MoreEli Lilly & Co. (LLY) gains after Novo Nordisk's monlunabant obesity data
September 20, 2024 9:23 AM EDTEli Lilly & Co. (NYSE: LLY) ticks higher following Novo Nordisk's update on Monlunabant phase 2a trial in obesity.
from Novo's release: "From a baseline body weight of 110.1 kg, all doses of monlunabant achieved a statistically significant weight loss compared to placebo. After 16... More
Eli Lilly & Co. (LLY) option IV near lower end of range
September 19, 2024 5:53 AM EDTEli Lilly & Co. (NYSE: LLY) 30-day option implied volatility is at 28; compared to its 52-week range of 22 to 55 on 100K contracts with a focus on September calls.
... More